Figure 1.
Overall survival (OS) after treatment with azacitidine ± DLI for relapse of myeloid neoplasms. OS of the study population comprising 151 patients was 38% (±9%) at 2 years.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.